Strategic expansion driven by AI integration, point-of-care diagnostics, and telemedicine transformation reshape medical ...
On April 9, 2026, Oxford BioTherapeutics announced a multi-year collaboration with Bristol Myers Squibb focused on the discovery and development of T-cell engager therapies for solid tumors. 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results